hocine-1

Hocine Sidi-Said

FOUNDER & CHIEF EXECUTIVE OFFICER

Three decades operating, investing and advising at the intersection of pharmaceuticals and capital — across more than thirty emerging markets.

Hocine is the Founder and Chief Executive Officer of Bio-nAbler, the life sciences advisory and investment platform he established in 2010 to serve sovereign wealth funds, private equity firms and life sciences operators across Emerging Markets. Over a thirty-year career, he has held P&L leadership positions at Pfizer, UCB and TPG-backed moksha8; co-founded the GCC's largest specialty biopharmaceutical platform; and advised some of the world's most significant institutional investors on the deployment of life sciences capital.

In 2020, Hocine co-founded Kelix Bio alongside long-time venture partner Alhadi Alwazir. As Chief Executive Officer, he built Kelix into a regional specialty biopharmaceutical leader with operations across the GCC, India, Egypt, Morocco and Malta — backed by CDC Group, Development Partners International and the European Bank for Reconstruction and Development. Kelix Bio was acquired by Mubadala in late 2024.

Earlier, Hocine spent seventeen years at Pfizer in senior management roles across the Middle East, Central and Eastern Europe and Asia, including Managing Director assignments in Indonesia, Denmark and India. He subsequently served as Executive Vice President for Emerging Markets at UCB (2005–2008) and as Executive Vice President and Partner at moksha8, the TPG-backed Latin America pharmaceutical platform (2008–2010).

Through Bio-nAbler, Hocine has advised the Saudi Public Investment Fund, ADQ, the Abu Dhabi Investment Council, Mumtalakat and Development Partners International, among others, on life sciences strategy, transactions and portfolio value creation. He currently serves as Chairman of Celon Laboratories (Hyderabad) and as a non-executive director of Bayti Home Health (Abu Dhabi), Bharat Home Medicare (Chennai), Antaria (a French pharmacy consolidation platform) and Mango Sciences (a real-world evidence and AI healthtech business). Between 2009 and 2014, he served as a non-executive director and Chairman of the Audit Committee of Glenmark Pharmaceuticals, then a US$1.6Bn revenue, US$2.4Bn market-cap company.

Hocine holds a Bachelor of Business Administration from Schiller International University and has completed senior leadership programs at Harvard Business School. He is fluent in English, French, Arabic and Berber.